Ocugen, Inc. (OCGN)

↓ Download CSV

CIK 0001372299 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Ocugen, Inc. reported revenue of $4.41M, up 8.8% from the prior year. The company ran a net loss, with a net margin of -1537.4%. It held $43.52M in total assets against $55.68M in total liabilities.

Key ratios (FY2025)

-1425.7%
Operating margin
-1537.4%
Net margin
+8.8%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$4.41M$4.05M$6.04M$2.49M$0$0
Operating Income-$62.92M-$54.76M-$65.53M-$89.07M-$58.03M-$21.29M-$14.16M-$16.14M-$24.95M-$30.31M
Net Income-$67.85M-$54.05M-$63.08M-$86.80M-$58.37M-$21.82M-$20.24M-$18.22M-$26.41M-$16.21M
EPS (Diluted)$-0.26$-0.40$-0.30$-0.31$-1.46$-0.79$-0.99$-2.18
Total Assets$43.52M$82.44M$64.55M$108.63M$105.76M$27.38M$16.81M$2.45M$11.04M$36.08M
Total Liabilities$55.68M$52.81M$23.98M$34.65M$9.94M$5.83M$5.79M$15.16M$22.30M$22.51M
Shareholders' Equity-$12.17M$29.63M$40.56M$73.98M$91.20M$21.55M$11.02M-$12.71M$4.43M$13.57M
Cash & Equivalents$39.46M$77.56M$94.96M$24.04M$7.44M$1.63M$7.08M$31.91M
Operating Cash Flow-$56.96M-$42.14M-$62.05M-$60.08M-$47.94M-$14.71M-$16.89M-$11.63M-$23.02M
Capital Expenditures$185.0K$3.38M$10.48M$4.46M$939.0K$307.0K$30.0K$77.4K$276.0K$320.0K
Shares Outstanding312.38M291.37M256.57M221.60M199.38M184.01M52.63M4.96M24.57M20.65M